Zacks Research Has Optimistic Outlook of CORT Q4 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Stock analysts at Zacks Research lifted their Q4 2026 earnings estimates for Corcept Therapeutics in a research report issued on Wednesday, September 16th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings per share of $0.68 for the quarter, up from their previous forecast of $0.62. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $2.02 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2027 earnings at $0.78 EPS, Q4 2027 earnings at $0.65 EPS, FY2027 earnings at $2.05 EPS and FY2028 earnings at $4.31 EPS.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.34. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The business had revenue of $256.15 million for the quarter, compared to analysts’ expectations of $221.15 million. During the same period in the previous year, the firm posted $0.29 EPS. The business’s revenue was up 31.7% on a year-over-year basis.

CORT has been the topic of several other reports. Piper Sandler reaffirmed an “overweight” rating and issued a $165.00 price target (up from $88.00) on shares of Corcept Therapeutics in a research note on Thursday, July 30th. Truist Financial assumed coverage on Corcept Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $164.00 price objective for the company. Wall Street Zen upgraded shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 1st. Canaccord Genuity Group upped their target price on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Finally, UBS Group set a $135.00 price target on shares of Corcept Therapeutics in a research note on Thursday, May 28th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Corcept Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $138.17.

Corcept Therapeutics Stock Up 0.9%

CORT opened at $111.81 on Thursday. The stock has a market cap of $12.09 billion, a PE ratio of 266.22 and a beta of 0.45. The business has a 50 day moving average of $107.76 and a 200-day moving average of $74.40. Corcept Therapeutics has a 52 week low of $28.66 and a 52 week high of $126.38.

Hedge Funds Weigh In On Corcept Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CORT. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Corcept Therapeutics in the second quarter worth about $27,000. State of Wyoming increased its stake in Corcept Therapeutics by 29.5% in the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 186 shares during the last quarter. Hantz Financial Services Inc. raised its holdings in shares of Corcept Therapeutics by 113.7% during the 4th quarter. Hantz Financial Services Inc. now owns 985 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 524 shares in the last quarter. Gould Capital LLC raised its holdings in shares of Corcept Therapeutics by 66.7% during the 1st quarter. Gould Capital LLC now owns 1,000 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 400 shares in the last quarter. Finally, SHP Wealth Management bought a new position in shares of Corcept Therapeutics during the 4th quarter valued at approximately $72,000. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Roberto Vieira sold 58,333 shares of Corcept Therapeutics stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $110.76, for a total value of $6,460,963.08. Following the completion of the transaction, the insider owned 4,242 shares of the company’s stock, valued at $469,843.92. The trade was a 93.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Joseph Lyon sold 10,000 shares of the stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $113.49, for a total transaction of $1,134,900.00. Following the sale, the insider directly owned 5,683 shares in the company, valued at $644,963.67. This trade represents a 63.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 446,119 shares of company stock valued at $50,644,753. Company insiders own 20.70% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company’s research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases.

Corcept’s commercial product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.